US 12,215,168 B2
Anti-A2AP antibodies and uses thereof
Stefan Heitmeier, Wülfrath (DE); Julia Glunz, Essen (DE); Melanie Fischer, Riedstadt (DE); Cindy Schulenburg, Zürich (CH); Hannah Jörißen, Heiligenhaus (DE); Christoph Thiel, Cologne (DE); Andreas Wilmen, Cologne (DE); and Ernst Weber, Langenfeld (DE)
Assigned to BAYER AKTIENGESELLSCHAFT, Leverkusen (DE)
Filed by BAYER AKTIENGESELLSCHAFT, Leverkusen (DE)
Filed on Nov. 30, 2023, as Appl. No. 18/525,736.
Application 18/525,736 is a continuation of application No. 18/329,700, filed on Jun. 6, 2023.
Application 18/329,700 is a continuation of application No. 18/026,089, previously published as PCT/EP2021/075038, filed on Sep. 13, 2021.
Claims priority of application No. 20196259 (EP), filed on Sep. 15, 2020.
Prior Publication US 2024/0166766 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/38 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 9/10 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/38 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 9/10 (2018.01); C12N 15/63 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 15 Claims
 
1. An isolated antibody or antigen-binding fragment thereof capable of binding to alpha 2 antiplasmin (A2AP) and inhibiting the activity of A2AP, comprising:
a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO: 6, an H-CDR2 comprising SEQ ID NO: 8, and an H-CDR3 comprising SEQ ID NO: 13 and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO: 9, an L-CDR2 comprising SEQ ID NO: 10, and an L-CDR3 comprising SEQ ID NO:18.